

# HYPERION+ Imaging System

*Moving at the speed of life.*



## Uncover spatial biology secrets. Gain disease insights.

Imaging Mass Cytometry™ (IMC™) allows scientists to gain an appreciation of the role of heterogeneity in cell function. Researchers globally have been using IMC on the Hyperion™ Imaging System. Now, the next milestone in high-plex tissue imaging is here – go twice as fast with the Hyperion+ Imaging System and assess more than 100 samples a week.

### The new high-plex imaging standard

The Hyperion+ Imaging System is the new standard to assess tumour-immune interactions and get deep single-cell insights into the spatial relationships of cells, pathways and phenotypes in the tumour microenvironment. Using this system, you can:

- better understand disease and response to treatment
- stratify subjects by linking high-plex data to outcomes in clinical studies
- uncover novel therapeutic targets.

The fast, hands-free workflow is ideal for cohort analysis and retrospective studies.

### Get high image quality with the Hyperion+ Imaging System

With the power of IMC, you can simultaneously examine more than 40 protein markers at subcellular resolution without spectral overlap or background autofluorescence to gain new insights from precious tissue samples and tissue microarrays. You will get high-quality, quantifiable images that can be spectrally separated to display the expression of each protein, yet the files remain small and easy to handle, ready for analysis with a third-party software such as histoCAT™, the Visiopharm® phenotyping module or Indica Labs HALO®.

### Accelerate success in cancer research and immunotherapy development

To obtain biological insights into cancer, there are many elements of the tumour microenvironment to consider: stroma, vascularisation, nutrients in blood flow, fibrotic regions and various immune cell phenotypes and interactions. IMC does more than help you understand the cell repertoire. It reveals cell function, especially in the context of spatial localisation and cell-to-cell communication. Numerous published studies as well as ongoing clinical trials demonstrate IMC use

in cancer and immuno-oncology research. IMC is a key tool for a multi-omic approach to understanding the complex interactions essential to developing novel therapies and why existing therapies are successful or not. The growing trend for the use of IMC in cancer immunotherapy studies is therefore clear.

### The proven high-plex imaging approach with a streamlined workflow

Do not miss out because you think high-multiplex imaging is early-stage technology or too difficult to perform. Learn how your colleagues are already using this robust system to answer important clinical research questions in the context of disease. With nearly 200 peer-reviewed publications across a wide variety of disease areas and applications, there is already a wealth of information to help you get started.





Learn how you can accelerate your time to *insights*:  
[fluidigm.com/hyperion-plus](https://fluidigm.com/hyperion-plus)



The trusted high-plex imaging system for discovery and translational researchers.

Bridging discovery to clinical trials.

## Hyperion+<sup>TM</sup> Imaging System



Moving at the *speed* of life.

### Reliable

Get high-dimensional spatial information without the limitations of autofluorescence and repeat cyclic staining, to ensure better repeatability and consistency of results.

### Efficient

A streamlined workflow to get the most out of precious sample, with all-in-one-staining and standardized panels to uncover new findings.

### Proven

Powered by CyTOF<sup>®</sup> technology with nearly 200 publications and growing use in clinical trials.

See how a Hyperion+ Imaging System can contribute to the successful development of novel immunotherapies and advance your understanding of health and disease.

Learn how to reveal a more complete picture now at [fluidigm.com/hyperion-plus](https://fluidigm.com/hyperion-plus)

**For Research Use Only. Not for use in diagnostic procedures.**

**Patent and License Information:** [www.fluidigm.com/legal/notices](https://www.fluidigm.com/legal/notices). **Trademarks:** Standard BioTools, the Standard BioTools logo, Fluidigm, the Fluidigm logo, CyTOF, Hyperion, Hyperion+, Imaging Mass Cytometry and IMC are trademarks and/or registered trademarks of Standard BioTools Inc. (f.k.a. Fluidigm Corporation) or its affiliates in the United States and/or other countries. ©2022 Standard BioTools Inc. 08/2022